Lenacapavir complements existing prevention methods such as oral pre-exposure prophylaxis and long-acting injectable cabotegravir.
Trained health workers will conduct house-to-house visits and set up vaccination points at designated community locations to maximise coverage.
The Global Fund has provided USD 3 million for governance and capacity building, along with USD701 million in programmatic funding.
The warning comes after an official report from Roche Nigeria, which traced the fake products bearing batch number N2110A09 in Kaduna and Gombe States.
The alert followed official communication from Roche Nigeria after the pharmaceutical company received multiple complaints from healthcare professionals nationwide.
The complaints originated from Lagos University Teaching Hospital (LUTH-NSIA), where patients brought in suspected counterfeit products for administration.
The initiative supports broader efforts to improve tuberculosis detection as Nigeria approaches the final phase of its 2021–2026 National Strategic Plan.
NAFDAC released the public alert following a Notice of Concern from the WHO Prequalification service.
This strategic approach aligns with President Bola Tinubu’s broader vision to unlock the healthcare value chain by empowering local pharmaceutical industries.
The medical expert stressed that when chronic kidney disease is detected early, healthcare providers can effectively manage the condition and prevent its progression.